Modified Citrus Pectin Alleviates Cerebral Ischemia/Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation via TLR4/NF-ĸB Signaling Pathway in Microglia

References

• Campbell BCV, Khatri P. Stroke. Lancet. 2020;396(10244):129–142. doi:10.1016/S0140-6736(20)31179-X
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282. doi:10.1016/S0140-6736(07)60149-4
   PubMed Web of Science ®Google Scholar
• Yu WM, Abdul-Rahim AH, Cameron AC, et al. The incidence and associated factors of early neurological deterioration after thrombolysis: results from SITS registry. Stroke. 2020;51(9):2705–2714. doi:10.1161/STROKEAHA.119.028287
   PubMed Web of Science ®Google Scholar
• Shi K, Zou M, Jia D-M, et al. tPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke. Circ Res. 2021;128(1):62–75. doi:10.1161/CIRCRESAHA.120.317596
   PubMed Web of Science ®Google Scholar
• Petrovic-Djergovic D, Goonewardena SN, Pinsky DJ. Inflammatory disequilibrium in stroke. Circ Res. 2016;119(1):142–158. doi:10.1161/CIRCRESAHA.116.308022
   PubMed Web of Science ®Google Scholar
• Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87(5):779–789. doi:10.1189/jlb.1109766
   PubMed Web of Science ®Google Scholar
• Hernández IH, Villa-González M, Martín G, Soto M, Pérez-álvarez MJ. Glial cells as therapeutic approaches in brain ischemia-reperfusion injury. Cells. 2021;10(7):1639. doi:10.3390/cells10071639
   PubMed Web of Science ®Google Scholar
• Rahimian R, Béland LC, Kriz J. Galectin-3: mediator of microglia responses in injured brain. Drug Discov Today. 2018;23(2):375–381. doi:10.1016/j.drudis.2017.11.004
   PubMed Web of Science ®Google Scholar
• Burguillos MA, Svensson M, Schulte T, et al. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep. 2015;10(9):1626–1638. doi:10.1016/j.celrep.2015.02.012
   PubMed Web of Science ®Google Scholar
• Venkatraman A, Hardas S, Patel N, Singh Bajaj N, Arora G, Arora P. Galectin-3: an emerging biomarker in stroke and cerebrovascular diseases. Eur J Neurol. 2018;25(2):238–246. doi:10.1111/ene.13496
   PubMed Web of Science ®Google Scholar
• Kopitar-Jerala N. Innate immune response in brain, NF-Kappa B SIGNALING AND Cystatins. Front Mol Neurosci. 2015;8:73. doi:10.3389/fnmol.2015.00073
   PubMed Web of Science ®Google Scholar
• Xu S, Lu J, Shao A, Zhang JH, Zhang J. Glial cells: role of the immune response in ischemic stroke. Front Immunol. 2020;11:294. doi:10.3389/fimmu.2020.00294
   PubMed Web of Science ®Google Scholar
• Lau ES, Liu E, Paniagua SM, et al. Galectin-3 inhibition with modified citrus pectin in hypertension. JACC Basic Transl Sci. 2021;6(1):12–21. doi:10.1016/j.jacbts.2020.10.006
   PubMedGoogle Scholar
• Xu GR, Zhang C, Yang HX, et al. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway. Biomed Pharmacother. 2020;126:110071. doi:10.1016/j.biopha.2020.110071
   PubMed Web of Science ®Google Scholar
• Yin Q, Chen J, Ma S, et al. Pharmacological inhibition of Galectin-3 ameliorates diabetes-associated cognitive impairment, oxidative stress and neuroinflammation in vivo and in vitro. J Inflamm Res. 2020;13:533–542. doi:10.2147/JIR.S273858
   PubMed Web of Science ®Google Scholar
• Ibarrola J, Matilla L, Martínez-Martínez E, et al. Myocardial injury after ischemia/reperfusion is attenuated by pharmacological Galectin-3 inhibition. Sci Rep. 2019;9(1):9607. doi:10.1038/s41598-019-46119-6
   PubMed Web of Science ®Google Scholar
• Martínez-Martínez E, Calvier L, Fernández-Celis A, et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015;66(4):767–775. doi:10.1161/HYPERTENSIONAHA.115.05876
   PubMed Web of Science ®Google Scholar
• Dong H, Wang ZH, Zhang N, Liu SD, Zhao JJ, Liu SY. Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke. Oncotarget. 2017;8(65):109752–109761. doi:10.18632/oncotarget.18211
   PubMedGoogle Scholar
• Wang A, Zhong C, Zhu Z, et al. Serum Galectin-3 and poor outcomes among patients with acute ischemic stroke. Stroke. 2018;49(1):211–214. doi:10.1161/STROKEAHA.117.019084
   PubMed Web of Science ®Google Scholar
• Zeng N, Wang A, Zhong C, et al. Association of serum galectin-3 with risks of death and vascular events in acute ischaemic stroke patients: the role of hyperglycemia. Eur J Neurol. 2019;26(3):415–421. doi:10.1111/ene.13856
   PubMed Web of Science ®Google Scholar
• Zeng N, Wang A, Xu T, et al. Co-effect of serum Galectin-3 and high-density lipoprotein cholesterol on the prognosis of acute ischemic stroke. J Stroke Cerebrovasc Dis. 2019;28(7):1879–1885. doi:10.1016/j.jstrokecerebrovasdis.2019.04.007
   PubMed Web of Science ®Google Scholar
• Hansen C, Sastre C, Wolcott Z, Bevers MB, Kimberly WT. Time-dependent, dynamic prediction of fatty acid-binding protein 4, Galectin-3, and soluble ST2 measurement with poor outcome after acute stroke. Int J Stroke. 2021;16(6):660–668. doi:10.1177/1747493020971166
   PubMed Web of Science ®Google Scholar
• Zhuang JJ, Zhou L, Zheng YH, Ding YS. The serum galectin-3 levels are associated with the severity and prognosis of ischemic stroke. Aging. 2021;13(5):7454–7464. doi:10.18632/aging.202610
   PubMedGoogle Scholar
• Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Cereb Blood Flow Metab. 2020;40(9):1769–1777. doi:10.1177/0271678X20943823
   PubMed Web of Science ®Google Scholar
• Vahidy F, Schäbitz WR, Fisher M, Aronowski J. Reporting standards for preclinical studies of stroke therapy. Stroke. 2016;47(10):2435–2438. doi:10.1161/STROKEAHA.116.013643
   PubMed Web of Science ®Google Scholar
• Wu LR, Liu L, Xiong XY, et al. Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling. Oncotarget. 2017;8(46):80315–80324. doi:10.18632/oncotarget.20699
   PubMedGoogle Scholar
• Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91. doi:10.1161/01.str.20.1.84
   PubMed Web of Science ®Google Scholar
• Hatashita S, Hoff JT, Salamat SM. Ischemic brain edema and the osmotic gradient between blood and brain. J Cereb Blood Flow Metab. 1988;8(4):552–559. doi:10.1038/jcbfm.1988.96
   PubMed Web of Science ®Google Scholar
• Qin X, Sun ZQ, Zhang XW, Dai XJ, Mao SS, Zhang YM. TLR4 signaling is involved in the protective effect of propofol in BV2 microglia against OGD/reoxygenation. J Physiol Biochem. 2013;69(4):707–718. doi:10.1007/s13105-013-0247-6
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qin P, Deng Y, et al. The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation. J Neuroinflammation. 2018;15(1):206. doi:10.1186/s12974-018-1246-x
   PubMed Web of Science ®Google Scholar
• Ma Z, Zhang Z, Bai F, Jiang T, Yan C, Wang Q. Electroacupuncture pretreatment alleviates cerebral ischemic injury through α7 nicotinic acetylcholine receptor-mediated phenotypic conversion of microglia. Front Cell Neurosci. 2019;13:537. doi:10.3389/fncel.2019.00537
   PubMed Web of Science ®Google Scholar
• Ma C, Liu S, Zhang S, et al. Evidence and perspective for the role of the NLRP3 inflammasome signaling pathway in ischemic stroke and its therapeutic potential (Review). Int J Mol Med. 2018;42(6):2979–2990. doi:10.3892/ijmm.2018.3911
   PubMed Web of Science ®Google Scholar
• Hong P, Gu RN, Li FX, et al. NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes. J Neuroinflammation. 2019;16(1):121. doi:10.1186/s12974-019-1498-0
   PubMed Web of Science ®Google Scholar
• Yang G, Jang JH, Kim SW, et al. Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasome. Int J Mol Sci. 2020;21(8):2790. doi:10.3390/ijms21082790
   PubMed Web of Science ®Google Scholar
• Fann DY, Lee SY, Manzanero S, Chunduri P, Sobey CG, Arumugam TV. Pathogenesis of acute stroke and the role of inflammasomes. Ageing Res Rev. 2013;12(4):941–966. doi:10.1016/j.arr.2013.09.004
   PubMed Web of Science ®Google Scholar
• Alishahi M, Farzaneh M, Ghaedrahmati F, Nejabatdoust A, Sarkaki A, Khoshnam SE. NLRP3 inflammasome in ischemic stroke: as possible therapeutic target. Int J Stroke. 2019;14(6):574–591. doi:10.1177/1747493019841242
   PubMed Web of Science ®Google Scholar
• Zhang Q, Chen C, Lü J, et al. Cell cycle inhibition attenuates microglial proliferation and production of IL-1beta, MIP-1alpha, and NO after focal cerebral ischemia in the rat. Glia. 2009;57(8):908–920. doi:10.1002/glia.20816
   PubMed Web of Science ®Google Scholar
• Guadagno J, Swan P, Shaikh R, Cregan SP. Microglia-derived IL-1β triggers p53-mediated cell cycle arrest and apoptosis in neural precursor cells. Cell Death Dis. 2015;6(6):e1779. doi:10.1038/cddis.2015.151
   PubMed Web of Science ®Google Scholar
• Rühl A, Franzke S, Stremmel W. IL-1beta and IL-10 have dual effects on enteric glial cell proliferation. Neurogastroenterol Motil. 2001;13(1):89–94. doi:10.1046/j.1365-2982.2001.00245.x
   PubMed Web of Science ®Google Scholar
• Boato F, Hechler D, Rosenberger K, et al. Interleukin-1 beta and neurotrophin-3 synergistically promote neurite growth in vitro. J Neuroinflammation. 2011;8(1):183. doi:10.1186/1742-2094-8-183
   PubMed Web of Science ®Google Scholar